J Formos Med Assoc
-
Observational Study
Pharmacokinetics and dosing of vancomycin in patients undergoing sustained low efficiency daily diafiltration (SLEDD-f): A prospective study.
The pharmacokinetics of vancomycin in patients who undergo sustained low efficiency daily diafiltration (SLEDD-f) is not clear. This study aimed to determine the appropriate vancomycin dosage regimen for patients receiving SLEDD-f. ⋯ Significant amount of vancomycin removed during SLEDD-f. Despite the existence of post-dialysis rebound, a sufficient supplemental dose is necessary to maintain therapeutic range.
-
The biochemical response is a crucial indicator of prognosis in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues (NAs). The impact of hepatitis D virus (HDV) infection on alanine aminotransferase normalization is elusive. ⋯ HDV infection played an important role in ALT abnormality in CHB patients receiving 1-year and 2-year NAs. The impact was particularly noted in patients who had successfully suppressed HBV DNA.
-
Few studies have assessed the long-term impact of inhaled corticosteroids (ICS) in preterm infants. This study evaluated the neurodevelopmental outcomes of chronically ventilated extremely low birth weight (ELBW) preterm infants exposed to ICS. ⋯ The late ICS exposure was not associated with neurodevelopmental impairment at 24 months corrected age in chronically ventilated ELBW infants; however, it did not reduce the duration of their dependence on oxygen and mechanical ventilation.
-
Recent studies reported that driving pressure has been associated with increased mortality in acute respiratory distress syndrome (ARDS) patients. We aimed to explore the association between 28-day mortality and driving pressure in patients with severe pneumonia without ARDS. ⋯ Driving pressure was associated with 28-day mortality in patients with severe pneumonia without ARDS.
-
The purpose of the work is to analyze population adaptation to SARS-CoV-2 in Europe in March-May 2020, predict herd immunity formation in the nearest several months on the basis of our SIR modified epidemiological model of the virus spread and elaborate recommendations to governments regarding a second wave of COVID-19 pandemic. ⋯ In case of a second wave of COVID-19 disease in Europe, it will coincide with seasonal common cold surge, spanning from mid-September 2020 to mid-February 2021, with a median in November-December 2020. Strict epidemiological surveillance must be observed in Europe at that time.